{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:13:39Z","timestamp":1793862819190,"version":"4.6.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Immunomodulatory treatment options for multiple sclerosis show an inverse risk\u2012benefit ratio of side effects and treatment efficacy. Although rare, anti-B-cell therapies can cause acute or late-onset neutropenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We report a case of severe recurrent fluctuating neutropenia after ofatumumab treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed four recurrences even after pausing with ofatumumab and repeated granulocyte stimulating factor (G-CSF) treatment. In total, neutropenia occurred five times and was associated with recurrent pulmonary, urinary tract, and skin infections. Bone marrow investigation revealed no signs of lymphoma or leukemia. Interestingly, routine molecular testing revealed two gene variants of unknown significance for <jats:italic>BCORL1<\/jats:italic> and <jats:italic>ASXL1<\/jats:italic>, both of which play a role in hematopoiesis. The neutrophil count recovered spontaneously six months after the cessation of treatment with ofatumumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This case highlights the necessity of identifying patients at risk and monitoring white blood cell counts regularly for up to 6 months after initial neutropenia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00377-0","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T23:03:56Z","timestamp":1742771036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recurrent late-onset neutropenia after ofatumumab treatment in a case of multiple sclerosis"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-4121","authenticated-orcid":false,"given":"Jessy","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Laumeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Siffrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"377_CR1","doi-asserted-by":"publisher","first-page":"105147","DOI":"10.1016\/j.msard.2023.105147","volume":"81","author":"V Pang","year":"2024","unstructured":"Pang, V., Seery, N., Wesselingh, R., Yeh, W., Zhong, M., Tan, T., et al. (2024). Neutropaenia complications from Ocrelizumab and rituximab treatment. Mult Scler Relat Disord, 81, 105147.","journal-title":"Mult Scler Relat Disord"},{"key":"377_CR2","doi-asserted-by":"publisher","first-page":"104090","DOI":"10.1016\/j.msard.2022.104090","volume":"68","author":"L Rossi","year":"2022","unstructured":"Rossi, L., Dinoto, A., Bratina, A., Baldini, S., Pasquin, F., Bosco, A., et al. (2022). Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: A retrospective case series and a systematic review of reported cases. Mult Scler Relat Disord, 68, 104090.","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"377_CR3","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser, S. L., Kappos, L., Montalban, X., Craveiro, L., Chognot, C., Hughes, R., et al. (2021). Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology, 97(16), e1546\u2013e59.","journal-title":"Neurology"},{"issue":"1","key":"377_CR4","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","volume":"4","author":"RR Furman","year":"2017","unstructured":"Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., et al. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenstr\u00f6m\u2019s macroglobulinaemia: An open-label, single-arm, phase 2 study. Lancet Haematol, 4(1), e24\u2013e34.","journal-title":"Lancet Haematol"},{"issue":"6","key":"377_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., et al. (2020). Ofatumumab versus Teriflunomide in multiple sclerosis. New England Journal of Medicine, 383(6), 546\u2013557.","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"377_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-019-0260-2","volume":"9","author":"M van Oers","year":"2019","unstructured":"van Oers, M., Smolej, L., Petrini, M., Offner, F., Grosicki, S., Levin, M. D., et al. (2019). Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: Final analysis of the PROLONG study. Blood Cancer J, 9(12), 98.","journal-title":"Blood Cancer J"},{"key":"377_CR7","doi-asserted-by":"crossref","unstructured":"Baker, D., Kang, A. S., Giovannoni, G., & Schmierer, K. (2024). Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis. Multiple Sclerosis and Related Disorders.;82.","DOI":"10.1016\/j.msard.2023.105400"},{"key":"377_CR8","doi-asserted-by":"crossref","unstructured":"Protopapa, M., Schraad, M., Pape, K., Steffen, F., Steenken, L., Zipp, F. (2024). Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis. Med.:100529.","DOI":"10.1016\/j.medj.2024.10.006"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"104015","DOI":"10.1016\/j.msard.2022.104015","volume":"65","author":"H Hammer","year":"2022","unstructured":"Hammer, H., Kamber, N., Pistor, M., Diem, L., Friedli, C., Chan, A., et al. (2022). Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA adverse event reporting system (FAERS). Multiple Sclerosis and Related Disorders, 65, 104015.","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"377_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41375-022-01792-x","volume":"37","author":"TP Braun","year":"2023","unstructured":"Braun, T. P., Estabrook, J., Schonrock, Z., Curtiss, B. M., Darmusey, L., Macaraeg, J., et al. (2023). Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors. Leukemia, 37(2), 478\u2013487.","journal-title":"Leukemia"},{"issue":"1","key":"377_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato, T., Dumitriu, B., Hosokawa, K., Makishima, H., Yoshida, K., Townsley, D., et al. (2015). Somatic mutations and clonal hematopoiesis in aplastic Anemia. New England Journal of Medicine, 373(1), 35\u201347.","journal-title":"New England Journal of Medicine"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00377-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T23:04:00Z","timestamp":1742771040000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00377-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00377-0","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is covered by the Charit\u00e9 Treatment Contract based on the EU-Datenschutzgrundverordnung (DSGVO) and Berliner Datenschutzgesetz\u2013BlnDSG. The patient was informed about the case report publication and signed a consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The patient was informed about the case report publication and signed a consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}